

Actinium Pharmaceuticals, Inc. (ATNM)

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001388320

Actinium Pharmaceuticals, Inc.		
ATNM; healthcare		
Grade	None 5 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025	
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$12.5M to \$120M assets total assets \$51.8M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	thin data, degenerate inputs; fortress balance sheet not computable: distress	
Inputs computable	5 of 14	
Graded from	filings received through Mar 30, 2026 193 days before the rescan; latest periodic filing 10-Q received Aug 7, 2026	
Last close	\$1.08 2026-10-08; market equity \$34.0M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 30, 2026

We are a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. We are focused on employing a biology-driven approach to develop differentiated, first-in-class radiopharmaceutical therapeutics for patients with solid tumors and hematologic malignancies. Our mission is to transform cancer treatment by delivering innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining our deep understanding of tumor biology and translational medicine with our expertise in radiochemistry.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 31.0						

Gross profitability		not computable	32.2%			latest aligned inputs end 2021-12-31; latest annual assets end 2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(14.5%)	(6.6%)	31.0	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 2
Solvency, sleeve percentile 53.6						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(25.07)	(0.31)	77.2	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			interest expense must exceed \$100,000
Current ratio		6.20x	2.96x	30.0	839	2025-12-31
Growth and financing, sleeve percentile 53.3						
Revenue growth, three-year compound		not computable	10.0%			four consecutive annual observations are required
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		(23.2%)	2.1%	86.9	704	2025-12-31
Net share issuance, one year		0.6%	2.5%	19.7	634	2026-03-30

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	5 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(36.3%)	8.0%	20
Distance from 52-week high	(36.1%)	(31.4%)	42
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(72.7%)	(1.0%)	8
Book value to price	0.89	0.28	84
Sales to price	0.00	0.31	4
Composite equity issuance, five years	49.1%	20.3%	66
Relative strength against the sector, log excess return	(0.66)	(0.14)	20

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$36.5M
Operating cash flow, four quarters	-\$22.7M
Months of runway	19.3
Days since last periodic filing	63 (10-Q received Aug 7, 2026)
Median daily dollar volume, 63 sessions	\$106,312

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	\$1.1M	2021-12-31	2023-03-31	10-K	0001213900-23-025597
2	cost of revenue	us-gaap:CostOfRevenue	\$900,000	2021-12-31	2022-03-25	10-K	0001213900-22-015208
3	assets	us-gaap:Assets	\$80.4M	2021-12-31	2023-03-31	10-K	0001213900-23-025597
4	net income	us-gaap:NetIncomeLoss	-\$33.9M	2025-12-31	2026-03-30	10-K	0001213900-26-036504
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$24.6M	2025-12-31	2026-03-30	10-K	0001213900-26-036504
6	assets	us-gaap:Assets	\$51.8M	2025-12-31	2026-03-30	10-K	0001213900-26-036504
7	assets	us-gaap:Assets	\$76.9M	2024-12-31	2026-03-30	10-K	0001213900-26-036504
8	current assets	us-gaap:AssetsCurrent	\$49.4M	2025-12-31	2026-03-30	10-K	0001213900-26-036504
9	current liabilities	us-gaap:LiabilitiesCurrent	\$8.0M	2025-12-31	2026-03-30	10-K	0001213900-26-036504
10	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$409.7M	2025-12-31	2026-03-30	10-K	0001213900-26-036504
11	operating income	us-gaap:OperatingIncomeLoss	-\$36.2M	2025-12-31	2026-03-30	10-K	0001213900-26-036504
12	book equity	us-gaap:StockholdersEquity	\$7.8M	2025-12-31	2026-03-30	10-K	0001213900-26-036504
13	liabilities	us-gaap:Liabilities	\$43.9M	2025-12-31	2026-03-30	10-K	0001213900-26-036504
14	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	\$900,000	2019-12-31	2020-05-08	10-K	0001213900-20-011475
15	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$9.3M	2019-12-31	2021-03-31	10-K	0001213900-21-019297
16	operating income	us-gaap:OperatingIncomeLoss	-\$22.1M	2019-12-31	2021-03-31	10-K	0001213900-21-019297
17	depreciation amortization	us-gaap:Depreciation	\$54,000	2019-12-31	2021-03-31	10-K	0001213900-21-019297
18	operating income	us-gaap:OperatingIncomeLoss	-\$26.8M	2016-12-31	2019-03-15	10-K	0001213900-19-004269
19	interest expense	us-gaap:InterestExpense	\$5,007	2016-12-31	2017-03-16	10-K	0001213900-17-002461
20	revenue	us-gaap:Revenues	\$90,000	2025-12-31	2026-03-30	10-K	0001213900-26-036504
21	revenue	us-gaap:Revenues	\$81,000	2023-12-31	2025-03-31	10-K	0001213900-25-026371

22	revenue	us-gaap:Revenues	\$1.0M	2022-12-31	2024-03-29	10-K	0001213900-24-028038
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$104,000	2025-12-31	2026-03-30	10-K	0001213900-26-036504
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$33.1M	2024-12-31	2026-03-30	10-K	0001213900-26-036504
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$11,000	2024-12-31	2026-03-30	10-K	0001213900-26-036504
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$47.3M	2023-12-31	2025-03-31	10-K	0001213900-25-026371
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$153,000	2023-12-31	2025-03-31	10-K	0001213900-25-026371
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$8.6M	2022-12-31	2024-03-29	10-K	0001213900-24-028038
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$366,000	2022-12-31	2024-03-29	10-K	0001213900-24-028038
30	assets	us-gaap:Assets	\$81.4M	2023-12-31	2025-03-31	10-K	0001213900-25-026371
31	assets	us-gaap:Assets	\$114.2M	2022-12-31	2024-03-29	10-K	0001213900-24-028038
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	31,374,994	2026-03-30	2026-03-30	10-K	0001213900-26-036504
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	31,195,891	2025-03-28	2025-03-31	10-K	0001213900-25-026371